RxSight, Inc.RXSTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-11.32%
↓ 562% below average
Average (22q)
2.45%
Historical baseline
Range
High:26.01%
Low:-18.07%
Volatility
1798.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -11.32% |
| Q2 2025 | -1.45% |
| Q1 2025 | 12.60% |
| Q4 2024 | 4.18% |
| Q3 2024 | 6.60% |
| Q2 2024 | 3.24% |
| Q1 2024 | 9.40% |
| Q4 2023 | 3.38% |
| Q3 2023 | -4.05% |
| Q2 2023 | 2.68% |
| Q1 2023 | 7.89% |
| Q4 2022 | 4.59% |
| Q3 2022 | 3.17% |
| Q2 2022 | -7.84% |
| Q1 2022 | 13.57% |
| Q4 2021 | 10.02% |
| Q3 2021 | -18.07% |
| Q2 2021 | -1.20% |
| Q1 2021 | 26.01% |
| Q4 2020 | -9.12% |
| Q3 2020 | 14.10% |
| Q2 2020 | -12.00% |
| Q1 2020 | 0.00% |